

Homeland Security Presidential Directive-10 “Biodefense for the 21st Century”

- Threat Awareness
- Prevention and Protection
- Surveillance and Detection
- Response and Recovery
 - Response Planning
 - Mass Casualty Care
 - Risk Communication
 - **Medical Countermeasure Development**
 - Decontamination



NIAID Strategic Plan for Biodefense Research



NIAID Biodefense Research Agenda for CDC Category A Agents



NIAID Biodefense Research Agenda for CDC Category A Agents

Progress Report



August 2003



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

Progress Report



June 2004




January 2003

Biodefense Countermeasure Development: Key Achievements


Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir



Anthrax


- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies



Biodefense Countermeasure Development: Key Achievements


Ebola

- Vaccine in human trials at NIAID Vaccine Research Center



Botulinum Toxin

- Development of vaccine and monoclonal/polyclonal antibodies



Influenza

- Development of vaccines against potential pandemic strains



Global Examples of Emerging and Re-Emerging Infectious Diseases

